Indian Journal of Critical Care Medicine

Register      Login



Volume / Issue

Online First

Related articles

VOLUME 26 , ISSUE 6 ( June, 2022 ) > List of Articles

Original Article

Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19

Rajeev Kasliwal, Srishti Suresh Jain, Rohit Jain, Divyansh Gupta, Priyamvada Gupta, Anand Jain, Rohan Tambi, Puneet Panwar, Munesh Meena, Ravi Jain

Keywords : Anti-inflammatory therapy, COVID-19, Cytokine storm, Immune modulation therapy, Retrospective study, Ulinastatin, Urinary trypsin inhibitor therapy

Citation Information : Kasliwal R, Jain SS, Jain R, Gupta D, Gupta P, Jain A, Tambi R, Panwar P, Meena M, Jain R. Effect of Urinary Trypsin Inhibitor (Ulinastatin) Therapy in COVID-19. Indian J Crit Care Med 2022; 26 (6):696-703.

DOI: 10.5005/jp-journals-10071-24156

License: CC BY-NC 4.0

Published Online: 20-06-2022

Copyright Statement:  Copyright © 2022; The Author(s).


Purpose: End-organ damage in coronavirus disease-2019 (COVID-19) is linked to “cytokine storm” and excessive release of inflammatory mediators. Various novel therapies have been used in COVID-19 including urinary trypsin inhibitor therapy. This study explores the efficacy of ulinastatin in COVID-19. Materials and methods: We retrieved the medical records of patients admitted during one month and did a propensity score analysis to create matched treatment and control groups. We analyzed these groups and the outcomes were presented with appropriate statistics. Survival curve was prepared to compare the survival effect of ulinastatin therapy at the end of hospitalization, among both the groups. Results: A total of 736 patients were admitted, and after adjusting the data with propensity score matching, 55 cases were selected by the system. On the final outcome analysis, we found that intensive care unit (ICU) length of stay [median (interquartile range) days 3 (3.5–7.8) vs 2 (0-4); p-value 0.28] in control vs intervention groups, and in hospital mortality (odds ratio: 0.491, CI 95%: 0.099–2.44, p-value 0.435) were not statistically different among the groups. In survival plot analysis also, there was no statistical difference (p-value 0.414) among both the groups.Conclusion: In this retrospective study, we conclude that the final outcome of the ICU length of stay, and overall, in hospital mortality were not different among both the groups. Hence, adequately powered randomized control trials are urgently required to confirm any benefit of ulinastatin therapy in COVID-19 treatment.

  1. WHO Coronavirus (COVID-19) Dashboard [Internet]. [cited 2021 Sep 27]. Available from:
  2. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol [Internet] 2017;39(5):529–539. Available from:
  3. Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): expert management considerations. Indian J Crit Care Med [Internet] 2020;24(6):429–434. Available from:
  4. Leisman DE, Ronner L, Pinotti R, Taylor MD, Sinha P, Calfee CS, et al. Cytokine elevation in severe and critical COVID-19: a rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes. Lancet Respir Med [Internet] 2020;8(12):1233–1244. Available from:
  5. Wilson JG, Simpson LJ, Ferreira A-M, Rustagi A, Roque J, Asuni A, et al. Cytokine profile in plasma of severe COVID-19 does not differ from ARDS and sepsis. JCI Insight 2020;5(17):140289.
  6. Mehta Y, Dixit SB, Zirpe KG, Ansari AS. Cytokine storm in novel coronavirus disease (COVID-19): expert management considerations. Indian J Crit Care Med 2020;24(6):429–434.
  7. Lin H-Y. The severe COVID-19: A sepsis induced by viral infection and its immunomodulatory therapy. Chin J Traumatol Zhonghua Chuang Shang Za Zhi 2020;23(4):190–195.
  8. Horie S, McNicholas B, Rezoagli E, Pham T, Curley G, McAuley D, et al. Emerging pharmacological therapies for ARDS: COVID-19 and beyond. Intensive Care Med 2020;46(12):2265–2283.
  9. Allegra A, Di Gioacchino M, Tonacci A, Musolino C, Gangemi S. Immunopathology of SARS-CoV-2 infection: immune cells and mediators, prognostic factors, and immune-therapeutic implications. Int J Mol Sci 2020;21(13):E4782.
  10. Feng Z, Shi Q, Fan Y, Wang Q, Yin W. Ulinastatin and/or thymosin α1 for severe sepsis: a systematic review and meta-analysis. J Trauma Acute Care Surg 2016;80(2):335–340.
  11. Zhang Y, Chen H, Li Y, Zheng S, Chen Y, Li L, et al. Thymosin alpha1- and ulinastatin-based immunomodulatory strategy for sepsis arising from intra-abdominal infection due to carbapenem-resistant bacteria. J Infect Dis 2008;198(5):723–730.
  12. Zhang X, Zhu Z, Jiao W, Liu W, Liu F, Zhu X. Ulinastatin treatment for acute respiratory distress syndrome in China: a meta-analysis of randomized controlled trials. BMC Pulm Med [Internet] 2019;19(1):196. Available from:
  13. Wang L-Z, Luo M-Y, Zhang J-S, Ge F-G, Chen J-L, Zheng C-Q. Effect of ulinastatin on serum inflammatory factors in Asian patients with acute pancreatitis before and after treatment: a meta-analysis. Int J Clin Pharmacol Ther 2016;54(11):890–898.
  14. Pang X-Y, Fang C-C, Chen Y-Y, Liu K, Song G-M. Effects of Ulinastatin on perioperative inflammatory response and pulmonary function in cardiopulmonary bypass patients. Am J Ther 2016;23(6): e1680–e1689.
  15. Shu H, Liu K, He Q, Zhong F, Yang L, Li Q, et al. Ulinastatin, a protease inhibitor, may inhibit allogeneic blood transfusion-associated pro-inflammatory cytokines and systemic inflammatory response syndrome and improve postoperative recovery. Blood Transfus Trasfus Sangue 2014;12 (1):s109–s118.
  16. Anderson PS (trad). Shanghai 2019 coronavirus disease comprehensive treatment expert consensus. 2020 Mar 24 [cited 2021 Sep 26]. Available from:
  17. UpdatedClinicalManagementProtocolforCOVID19dated03072020.pdf [Internet]. [cited 2021 Mar 1]. Available from:
  18. Alhazzani W, Evans L, Alshamsi F, Møller MH, Ostermann M, Prescott HC, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: First Update. Crit Care Med [Internet] 2021;49(3):e219–e234. Available from:
  19. WHO-2019-nCoV-clinical-2020.5-eng.pdf.
  20. Mulchandani R, Lyngdoh T, Kakkar AK. Deciphering the COVID-19 cytokine storm: systematic review and meta-analysis. Eur J Clin Invest 2021;51(1):e13429.
  21. Shao Y, Zhang L, Deng L, Yao H. [Clinical study on effects of ulinastatin on patients with systemic inflammatory response syndrome]. Zhongguo Wei Zhong Bing Ji Jiu Yi Xue Chin Crit Care Med Zhongguo Weizhongbing Jijiuyixue 2005;17(4):228–230.
  22. Huang Y, Xie K, Zhang J, Dang Y, Qiong Z. Prospective clinical and experimental studies on the cardioprotective effect of ulinastatin following severe burns. Burns J Int Soc Burn Inj 2008;34(5):674–680.
  23. Meng C, Qian Y, Zhang W-H, Liu Y, Song X-C, Liu H, et al. A retrospective study of ulinastatin for the treatment of severe sepsis. Medicine (Baltimore) 2020;99(49):e23361.
  24. Sun R, Li Y, Chen W, Zhang F, Li T. Total ginsenosides synergize with ulinastatin against septic acute lung injury and acute respiratory distress syndrome. Int J Clin Exp Pathol 2015;8(6):7385–7390.
  25. Chen T-T, Jiandong-Liu null, Wang G, Jiang S-L, Li L-B, Gao C-Q. Combined treatment of ulinastatin and tranexamic acid provides beneficial effects by inhibiting inflammatory and fibrinolytic response in patients undergoing heart valve replacement surgery. Heart Surg Forum 2013;16(1):E38–E47.
  26. Hao X, Han J, Xing Z, Hao Y, Jiang C, Zhang J, et al. Urinary trypsin inhibitor attenuated inflammatory response of patients undergoing cardiopulmonary bypass by inducing activated Treg cells. Inflammation 2013;36(6):1279–1285.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.